Incyte's EBIT per Share for the
three
months ended in Dec. 2023 was $1.20.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.70.
During the past 12 months, the average EBIT per Share Growth Rate of Incyte was 8.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Incyte's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Incyte was 210.70% per year. The lowest was -241.20% per year. And the median was 10.90% per year.
INCY's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.2 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Incyte's EBIT for the
three
months ended in Dec. 2023 was $272 Mil.
Incyte EBIT per Share Historical Data
The historical data trend for Incyte's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (NAS:INCY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Incyte EBIT per Share Related Terms
Thank you for viewing the detailed overview of Incyte's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INCY has been successfully added to your 